Michele Morari - Publications

Affiliations: 
2012-2012 Medical Science Università di Ferrara, Ferrara, Emilia-Romagna, Italy 

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Marti M, Mercatelli D, Pisanò CA, Brugnoli A, Morari M, Zaveri NT. Discovery and Structure-activity Relationships of Nociceptin Receptor Partial Agonists that Afford Symptom Ablation in Parkinson's Disease Models. Journal of Medicinal Chemistry. PMID 31951130 DOI: 10.1021/acs.jmedchem.9b02134  0.36
2019 Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M. Managing Parkinson's disease: Moving ON with NOP. British Journal of Pharmacology. PMID 31648371 DOI: 10.1111/bph.14893  0.36
2019 Mazzocchi M, Wyatt SL, Mercatelli D, Morari M, Morales-Prieto N, Collins LM, Sullivan AM, O'Keeffe GW. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Frontiers in Cell and Developmental Biology. 7: 191. PMID 31572723 DOI: 10.3389/fcell.2019.00191  0.36
2019 Mercatelli D, Bolognesi P, Frassineti M, Pisanò CA, Longo F, Shimshek DR, Morari M. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes. Pharmacology Research & Perspectives. 7: e00484. PMID 31149340 DOI: 10.1002/prp2.484  0.48
2019 Mercatelli D, Pisanò CA, Novello S, Morari M. NOP Receptor Ligands and Parkinson's Disease. Handbook of Experimental Pharmacology. PMID 30689087 DOI: 10.1007/164_2018_199  0.36
2018 Russo I, Di Benedetto G, Kaganovich A, Ding J, Mercatelli D, Morari M, Cookson MR, Bubacco L, Greggio E. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. Journal of Neuroinflammation. 15: 297. PMID 30368241 DOI: 10.1186/s12974-018-1337-8  0.48
2018 Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice. Neurobiology of Disease. PMID 30172844 DOI: 10.1016/j.nbd.2018.08.018  0.48
2017 Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M. Antiparkinsonian and antidyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. British Journal of Pharmacology. PMID 29232769 DOI: 10.1111/bph.14123  0.36
2017 Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, et al. Role of LRRK2 in the regulation of dopamine receptor trafficking. Plos One. 12: e0179082. PMID 28582422 DOI: 10.1371/journal.pone.0179082  0.48
2017 Sacchi S, Novellis V, Paolone G, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassineti M, Bertolino A, Pollegioni L, Morari M, Maione S, et al. Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. Scientific Reports. 7: 46288. PMID 28393897 DOI: 10.1038/srep46288  0.32
2017 Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathologica Communications. 5: 22. PMID 28292328 DOI: 10.1186/s40478-017-0426-8  0.48
2017 Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P. Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28128334 DOI: 10.1038/npp.2017.20  0.48
2016 Arcuri L, Mercatelli D, Morari M. Parkinson's disease: no NOP, new hope. Oncotarget. PMID 28086211 DOI: 10.18632/oncotarget.13710  0.36
2016 Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/j.nbd.2016.01.016  0.48
2015 Brugnoli A, Napolitano F, Usiello A, Morari M. Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia. Neurobiology of Disease. 85: 155-163. PMID 26522958 DOI: 10.1016/j.nbd.2015.10.020  0.48
2015 Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, et al. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release. Parkinsonism & Related Disorders. 21: 1156-63. PMID 26282470 DOI: 10.1016/j.parkreldis.2015.07.025  0.48
2015 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, ... ... Morari M, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/j.pneurobio.2015.07.002  0.48
2015 Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26207892 DOI: 10.1002/mds.26326  0.48
2015 Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR. Selectivity and Anti-Parkinson's Potential of Thiadiazolidinone RGS4 Inhibitors. Acs Chemical Neuroscience. 6: 911-9. PMID 25844489 DOI: 10.1021/acschemneuro.5b00063  0.48
2015 Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, et al. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. Neurobiology of Aging. 36: 1890-902. PMID 25771393 DOI: 10.1016/j.neurobiolaging.2015.02.003  0.48
2015 Morari M, Fantin M. Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease. The Analyst. 140: 3830-9. PMID 25584655 DOI: 10.1039/c4an01918k  0.48
2015 Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity. Materials Science & Engineering. C, Materials For Biological Applications. 48: 294-300. PMID 25579926 DOI: 10.1016/j.msec.2014.12.014  0.48
2014 Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 12953-62. PMID 25253844 DOI: 10.1523/JNEUROSCI.4677-13.2014  0.48
2014 Longo F, Russo I, Shimshek DR, Greggio E, Morari M. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiology of Disease. 71: 62-73. PMID 25107341 DOI: 10.1016/j.nbd.2014.07.013  0.48
2014 Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, et al. LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Frontiers in Molecular Neuroscience. 7: 49. PMID 24904275 DOI: 10.3389/fnmol.2014.00049  0.48
2014 Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific Reports. 4: 3730. PMID 24429495 DOI: 10.1038/srep03730  0.48
2013 Viaro R, Calcagno M, Marti M, Borrelli E, Morari M. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands. Neuropharmacology. 72: 126-38. PMID 23643745 DOI: 10.1016/j.neuropharm.2013.04.046  0.48
2013 Mabrouk OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A, Parsons CG, Auberson YP, Morari M. GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. Acs Chemical Neuroscience. 4: 808-16. PMID 23611155 DOI: 10.1021/cn400016d  0.48
2013 Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111. British Journal of Pharmacology. 168: 863-79. PMID 22994368 DOI: 10.1111/j.1476-5381.2012.02219.x  0.48
2012 Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 16106-19. PMID 23152595 DOI: 10.1523/JNEUROSCI.6408-11.2012  0.48
2012 Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, et al. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain : a Journal of Neurology. 135: 1884-99. PMID 22561640 DOI: 10.1093/brain/aws101  0.48
2012 Buzzi A, Chikhladze M, Falcicchia C, Paradiso B, Lanza G, Soukupova M, Marti M, Morari M, Franceschetti S, Simonato M. Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiology of Disease. 47: 216-24. PMID 22538221 DOI: 10.1016/j.nbd.2012.04.005  0.48
2012 Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, Drechsler M, Mazzoni S, Menegatti E, Morari M, Cortesi R. Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 80: 306-14. PMID 22061262 DOI: 10.1016/j.ejpb.2011.10.015  0.48
2012 Mela F, Marti M, Bido S, Cenci MA, Morari M. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiology of Disease. 45: 573-82. PMID 22001605 DOI: 10.1016/j.nbd.2011.09.015  0.48
2011 Bido S, Marti M, Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. Journal of Neurochemistry. 118: 1043-55. PMID 21740438 DOI: 10.1111/j.1471-4159.2011.07376.x  0.48
2011 Fantin M, Morari M, Tison F, Fernagut PO. NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid. Neurological Research. 33: 444-7. PMID 21535946 DOI: 10.1179/1743132810Y.0000000002  0.48
2011 Viaro R, Morari M, Franchi G. Progressive motor cortex functional reorganization following 6-hydroxydopamine lesioning in rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 4544-54. PMID 21430155 DOI: 10.1523/JNEUROSCI.5394-10.2011  0.48
2011 Volta M, Viaro R, Trapella C, Marti M, Morari M. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Experimental Neurology. 228: 126-37. PMID 21215744 DOI: 10.1016/j.expneurol.2010.12.024  0.48
2010 Volta M, Mabrouk OS, Bido S, Marti M, Morari M. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. Journal of Neurochemistry. 115: 1543-55. PMID 20950413 DOI: 10.1111/j.1471-4159.2010.07061.x  0.48
2008 Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiology of Disease. 30: 430-8. PMID 18413287 DOI: 10.1016/j.nbd.2008.02.011  0.48
2005 Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, ... Morari M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9591-601. PMID 16237164 DOI: 10.1523/JNEUROSCI.2546-05.2005  0.48
2004 Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 6659-66. PMID 15282268 DOI: 10.1523/JNEUROSCI.0987-04.2004  0.48
2003 Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C, Morari M. Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease. The European Journal of Neuroscience. 18: 759-67. PMID 12925002 DOI: 10.1046/j.1460-9568.2003.02806.x  0.48
2003 Marti M, Paganini F, Stocchi S, Mela F, Beani L, Bianchi C, Morari M. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors. Journal of Neurochemistry. 84: 792-802. PMID 12562523 DOI: 10.1046/j.1471-4159.2003.01569.x  0.48
2003 Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calo' G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C, Morari M. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. British Journal of Pharmacology. 138: 91-8. PMID 12522077 DOI: 10.1038/sj.bjp.0705005  0.48
2001 Marti M, Paganini F, Stocchi S, Bianchi C, Beani L, Morari M. Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release. The European Journal of Neuroscience. 14: 1181-4. PMID 11683911 DOI: 10.1046/j.0953-816X.2001.01750.x  0.48
Show low-probability matches.